Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.
Camille C. Gunderson, MD
Advertisement
Articles by Camille C. Gunderson, MD
Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian CancerSeptember 19th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5